RXi Pharmaceuticals Corp (NASDAQ:RXII), a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology, today announced that Dr. Robert Galiano, one of the Company’s Principal Investigators for the RXI-109 clinical program, will present during The Plastic Surgery Foundation (PSF) Industry Summit. The Summit will take place on Sunday, October 18, 2015 from 3:30-4:45 p.m. EDT in Boston, Massachusetts. Dr. Galiano will present an overview of the Company’s dermal clinical program with RXI-109.
Dr. Robert Galiano is an Associate Professor and Director of Research in the Division of Plastic Surgery at Northwestern University Feinberg School of Medicine and a plastic surgeon at Northwestern Memorial Hospital. He is a Board-Certified Plastic Surgeon who is actively involved in several scar-related basic and clinical research studies. He is the Principal Investigator in clinical trials investigating the efficacy of various scar treatments, including RXI-109, as well as studies assessing the quality of scar evaluation methods. In addition, Dr. Galiano assisted in the development of the Northwestern University human abdominoplasty in vivo scar model, a novel research model to assess the efficacy of scar therapeutics.
The PSF Industry Summit provides a venue to gather real-time data and market research from ~ 60 respected American Society of Plastic Surgeon including leaders, symposia faculty, committee chairs, and investment advisors. This event will connect innovators, companies and key opinion leaders (KOLs) in plastic surgery to gain valuable feedback.
The PSF takes place during, ‘Plastic Surgery: The Meeting 2015’. Now in its 89th year and with more than 3,000 attendees, this conference is the world’s largest gathering of plastic surgeons and surgical medical professionals who are interested in bringing the most leading-edge clinical information to their practice, to enhance patient satisfaction and surgical outcomes. (Original Source)
Shares of RXi Pharmaceuticals Corp closed last Friday at $0.5 . RXII has a 1-year high of $2.18 and a 1-year low of $0.34. The stock’s 50-day moving average is $0.43 and its 200-day moving average is $0.51.
On the ratings front, H.C. Wainwright analyst Mark Breidenbach reiterated a Buy rating on RXII, with a price target of $3.50, in a report issued on September 1. The current price target implies an upside of 600.0% from current levels. According to TipRanks.com, Breidenbach has a total average return of 5.6%, a 40.0% success rate, and is ranked #1750 out of 3775 analysts.
RXi Pharmaceuticals Corpis a biotechnology company focused on discovering and developingtherapies addressing high unmet medical needs, in the areas of dermatology and ophthalmology.